Analyst Soumit Roy of JonesTrading reiterated a Buy rating on Oric Pharmaceuticals, boosting the price target to $20.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy has given his Buy rating due to a combination of factors surrounding Oric Pharmaceuticals’ promising developments in their prostate cancer program. The upcoming data updates in the fourth quarter of 2025 and the first quarter of 2026 are expected to provide significant insights into dose optimization and efficacy of their treatment, ORIC-944, particularly in combination with other therapies like apalutamide or darolutamide.
The anticipated data will focus on response rates, safety, and potential long-term benefits, with early results showing promising efficacy and safety profiles compared to competitors like Pfizer’s mevrometostat. Additionally, the company’s financial position, with substantial cash reserves, supports ongoing research and development efforts, reinforcing the positive outlook for ORIC’s stock.